What Will Happen to Hologic Incorporated (NASDAQ:HOLX) Next? The Stock Has Decline in Shorts

January 21, 2018 - By Nellie Frank

 What Will Happen to Hologic Incorporated (NASDAQ:HOLX) Next? The Stock Has Decline in Shorts

Investors sentiment decreased to 0.88 in Q3 2017. Its down 0.50, from 1.38 in 2017Q2. It is negative, as 75 investors sold Hologic, Inc. shares while 145 reduced holdings. 64 funds opened positions while 129 raised stakes. 265.54 million shares or 0.74% less from 267.53 million shares in 2017Q2 were reported.
Wells Fargo & Mn invested in 0.05% or 4.02M shares. Anchor Cap Advsr Limited Liability has invested 0.09% of its portfolio in Hologic, Inc. (NASDAQ:HOLX). Loomis Sayles And Limited Partnership holds 0.03% or 325,057 shares. Parnassus Ca owns 7.55M shares or 1.14% of their US portfolio. The North Carolina-based Parsec Fincl Management Inc has invested 0.35% in Hologic, Inc. (NASDAQ:HOLX). Bancshares Of America De invested in 0.01% or 1.16M shares. Shell Asset Mgmt Com has invested 0.02% in Hologic, Inc. (NASDAQ:HOLX). Tower Rech Capital Ltd (Trc) holds 0.03% of its portfolio in Hologic, Inc. (NASDAQ:HOLX) for 10,002 shares. Scout Invests Inc holds 530,665 shares or 0.53% of its portfolio. Gofen And Glossberg Ltd Liability Corporation Il holds 9,505 shares. Ubs Asset Mgmt Americas Inc owns 793,407 shares for 0.03% of their portfolio. Trexquant L P stated it has 0.46% in Hologic, Inc. (NASDAQ:HOLX). Toronto Dominion Financial Bank accumulated 106,369 shares or 0.01% of the stock. Riggs Asset Managment holds 0.03% of its portfolio in Hologic, Inc. (NASDAQ:HOLX) for 2,080 shares. Jane Street Lc reported 9,191 shares.

Since August 3, 2017, it had 0 insider buys, and 4 insider sales for $1.18 million activity. On Thursday, August 3 the insider ULLIAN ELAINE sold $276,908.

The stock of Hologic Incorporated (NASDAQ:HOLX) registered a decrease of 8.66% in short interest. HOLX’s total short interest was 11.18M shares in January as published by FINRA. Its down 8.66% from 12.24M shares, reported previously. With 2.76 million shares average volume, it will take short sellers 4 days to cover their HOLX’s short positions. The short interest to Hologic Incorporated’s float is 4.17%.

The stock decreased 0.89% or $0.39 during the last trading session, reaching $43.46. About 4.36M shares traded or 52.23% up from the average. Hologic, Inc. (NASDAQ:HOLX) has risen 29.21% since January 21, 2017 and is uptrending. It has outperformed by 12.51% the S&P500.

Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. The company has market cap of $11.98 billion. It operates through four divisions: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It has a 16.46 P/E ratio. The Diagnostics segment provides Aptima family of assays, target capture/nucleic acid extraction technology, transcription-mediated amplification technology, hybridization protection and dual kinetic assays, Procleix family of assays for blood screening, instrumentation, Invader chemistry platform, ThinPrep system, and rapid fetal fibronectin test.

Hologic, Inc. (NASDAQ:HOLX) Ratings Coverage

Among 17 analysts covering Hologic (NASDAQ:HOLX), 14 have Buy rating, 0 Sell and 3 Hold. Therefore 82% are positive. Hologic had 49 analyst reports since July 24, 2015 according to SRatingsIntel. The stock has “Buy” rating by Goldman Sachs on Thursday, August 3. The rating was upgraded by Needham on Thursday, January 28 to “Buy”. The rating was maintained by Barclays Capital with “Underweight” on Thursday, July 30. The firm earned “Buy” rating on Tuesday, August 1 by Needham. BTIG Research upgraded Hologic, Inc. (NASDAQ:HOLX) on Monday, October 26 to “Buy” rating. The stock of Hologic, Inc. (NASDAQ:HOLX) has “Equal Weight” rating given on Wednesday, September 2 by Barclays Capital. Needham maintained it with “Buy” rating and $5000 target in Friday, June 2 report. The firm has “Buy” rating by Needham given on Wednesday, July 5. Bank of America initiated the shares of HOLX in report on Friday, July 24 with “Buy” rating. Barclays Capital upgraded Hologic, Inc. (NASDAQ:HOLX) rating on Friday, September 23. Barclays Capital has “Overweight” rating and $44 target.

More notable recent Hologic, Inc. (NASDAQ:HOLX) news were published by: Bna.com which released: “Minerva Fails in Bid to Stop Sales of Hologic Device” on January 09, 2018, also Prnewswire.com with their article: “Hologic to Present at the 36th Annual JP Morgan Healthcare Conference” published on January 02, 2018, Prnewswire.com published: “Hologic to Announce Financial Results for the First Quarter of Fiscal 2018 on …” on January 08, 2018. More interesting news about Hologic, Inc. (NASDAQ:HOLX) were released by: Streetinsider.com and their article: “Hologic (HOLX) Appoints Namal Nawana to Board” published on January 11, 2018 as well as Prnewswire.com‘s news article titled: “Hologic Announces Pricing of Offering of $1 Billion of Senior Notes” with publication date: January 17, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.